You Haisheng, Teng Mengmeng, Gao Chun Xia, Yang Bo, Hu Sasa, Wang Taotao, Dong Yalin, Chen Siying
Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Front Med (Lausanne). 2021 Jul 14;8:680679. doi: 10.3389/fmed.2021.680679. eCollection 2021.
Elderly patients with non-small-cell lung cancer (NSCLC) exhibit worse reactions to anticancer treatments. Adenocarcinoma (AC) is the predominant histologic subtype of NSCLC, is diverse and heterogeneous, and shows different outcomes and responses to treatment. The aim of this study was to establish a nomogram that includes the important prognostic factors based on the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. We collected 53,694 patients of older than 60 who have been diagnosed with lung AC from the SEER database. Univariate and multivariate Cox regression analyses were used to screen the independent prognostic factors, which were used to construct a nomogram for predicting survival rates in elderly AC patients. The nomogram was evaluated using the concordance index (C-index), calibration curves, net reclassification index (NRI), integrated discrimination improvement (IDI), and decision-curve analysis (DCA). Elderly AC patients were randomly divided into a training cohort and validation cohort. The nomogram model included the following 11 prognostic factors: age, sex, race, marital status, tumor site, histologic grade, American Joint Committee for Cancer (AJCC) stage, surgery status, radiotherapy status, chemotherapy status, and insurance type. The C-indexes of the training and validation cohorts for cancer-specific survival (CSS) (0.832 and 0.832, respectively) based on the nomogram model were higher than those of the AJCC model (0.777 and 0.774, respectively). The CSS discrimination performance as indicated by the AUC was better in the nomogram model than the AJCC model at 1, 3, and 5 years in both the training cohort (0.888 vs. 0.833, 0.887 vs. 0.837, and 0.876 vs. 0.830, respectively) and the validation cohort (0.890 vs. 0.832, 0.883 vs. 0.834, and 0.880 vs. 0.831, respectively). The predicted CSS probabilities showed optimal agreement with the actual observations in nomogram calibration plots. The NRI, IDI, and DCA for the 1-, 3-, and 5-year follow-up examinations verified the clinical usability and practical decision-making effects of the new model. We have developed a reliable nomogram for determining the prognosis of elderly AC patients, which demonstrated excellent discrimination and clinical usability and more accurate prognosis predictions. The nomogram may improve clinical decision-making and prognosis predictions for elderly AC patients.
老年非小细胞肺癌(NSCLC)患者对抗癌治疗的反应较差。腺癌(AC)是NSCLC的主要组织学亚型,具有多样性和异质性,并且表现出不同的治疗结果和反应。本研究的目的是基于2010年至2015年的监测、流行病学和最终结果(SEER)数据库建立一个包含重要预后因素的列线图。我们从SEER数据库中收集了53694例年龄大于60岁且已被诊断为肺AC的患者。采用单因素和多因素Cox回归分析筛选独立预后因素,这些因素用于构建预测老年AC患者生存率的列线图。使用一致性指数(C指数)、校准曲线、净重新分类指数(NRI)、综合鉴别改善(IDI)和决策曲线分析(DCA)对列线图进行评估。老年AC患者被随机分为训练队列和验证队列。列线图模型包括以下11个预后因素:年龄、性别、种族、婚姻状况、肿瘤部位、组织学分级、美国癌症联合委员会(AJCC)分期、手术状态、放疗状态、化疗状态和保险类型。基于列线图模型的训练队列和验证队列的癌症特异性生存(CSS)的C指数(分别为0.832和0.832)高于AJCC模型(分别为0.777和0.774)。在训练队列(分别为0.888对0.833、0.887对0.837和0.876对0.830)和验证队列(分别为0.890对0.832、0.883对0.834和0.880对0.831)中,列线图模型在1年、3年和5年时由AUC表示的CSS鉴别性能均优于AJCC模型。预测的CSS概率在列线图校准图中与实际观察结果显示出最佳一致性。1年、3年和5年随访检查的NRI、IDI和DCA验证了新模型的临床实用性和实际决策效果。我们开发了一种可靠的列线图来确定老年AC患者的预后,该列线图表现出优异的鉴别能力和临床实用性以及更准确的预后预测。该列线图可能会改善老年AC患者的临床决策和预后预测。